• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Sera Prognostics Inc.

    2/22/22 6:11:59 AM ET
    $SERA
    Medical Specialities
    Health Care
    Get the next $SERA alert in real time by email
    SC 13G 1 d247489dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. ___)*

     

     

    Sera Prognostics, Inc.

    (Name of Issuer)

    Class A Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    81749D107

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (continued on the following pages)

     

     

     


    CUSIP No. 81749D107    13G        

     

      1    

      NAMES OF REPORTING PERSONS

     

      Anthem, Inc.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Indiana

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      3,201,271(1)

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      3,201,271(1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      3,201,271(1)

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

      N/A

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      10.1% (1)(2)

    12  

      TYPE OF REPORTING PERSON (See Instructions)

     

      CO

     

     

    (1)

    Consists of (i) 2,201,974 shares of Class A common stock held by ATH Holding Company, LLC (“ATH Holding”), a wholly-owned subsidiary of Anthem, Inc. (“Anthem”), and (ii) 999,297 shares of Class A common stock issuable upon the exercise of currently exercisable warrants held by ATH Holding (the “Warrant Shares”).

    (2)

    Based upon 29,293,831 and 1,405,259 shares of the Issuer’s Class A common stock and Class B common stock, respectively, outstanding as of November 5, 2021, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 9, 2021, plus the Warrant Shares.


    CUSIP No. 81749D107    13G        

     

      1    

      NAMES OF REPORTING PERSONS

     

      ATH Holding Company, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Indiana

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      3,201,271(1)

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      3,201,271(1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      3,201,271(1)

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

      N/A

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      10.1% (1)(2)

    12  

      TYPE OF REPORTING PERSON (See Instructions)

     

      OO

     

     

    (1)

    Consists of (i) 2,201,974 shares of Class A common stock held by ATH Holding, and (ii) the 999,297 Warrant Shares issuable upon the exercise of currently exercisable warrants held by ATH Holding.

    (2)

    Based upon 29,293,831 and 1,405,259 shares of the Issuer’s Class A common stock and Class B common stock, respectively, outstanding as of November 5, 2021, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 9, 2021, plus the Warrant Shares.


    Item 1.

     

      (a)

    Name of Issuer

    Sera Prognostics, Inc. (the “Issuer”)

     

      (b)

    Address of Issuer’s Principal Executive Offices

    2749 East Parleys Way, Suite 200 Salt Lake City, Utah 84109

    Item 2.

     

      (a)

    Name of Person Filing

    This Schedule 13G is being filed by Anthem, Inc., an Indiana corporation (“Anthem”), and ATH Holding Company, LLC, an Indiana limited liability company (“ATH Holding,” and together with Anthem, the “Reporting Persons”). ATH Holding is a wholly-owned subsidiary of Anthem. The securities reported herein as being held by Anthem and ATH Holding are all directly beneficially owned by ATH Holding. Anthem may be deemed to indirectly beneficially own the securities that are directly beneficially owned by ATH Holding. The Joint Filing Agreement between the Reporting Persons is attached hereto as Exhibit 99.1.

     

      (b)

    Address of Principal Business Office or, if none, Residence

     

      (i)

    Anthem: 220 Virginia Avenue, Indianapolis, IN 46204

     

      (ii)

    ATH Holding: c/o Anthem, Inc., 220 Virginia Avenue, Indianapolis, IN 46204

     

      (c)

    Citizenship

     

      (i)

    Anthem: Indiana

     

      (ii)

    ATH Holding: Indiana

     

      (d)

    Title of Class of Securities

    Class A common stock, par value $0.0001 per share

     

      (e)

    CUSIP Number

    81749D107

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under section 15 of the Act.
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act.
    (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act.
    (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940.
    (e)    ☐    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E).
    (f)    ☐    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F).
    (g)    ☐    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).


    (h)    ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.

    (i)

       ☐   

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the

         

    Investment Company Act of 1940.

    (j)

      

    ☐

      

    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).

    (k)

      

    ☐

      

    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    Item 4.

    Ownership

     

      (a)

    Amount Beneficially Owned

     

    (i) Anthem:    3,201,271 shares*
    (ii) ATH Holding:    3,201,271 shares*

     

      *

    Consists of (i) 2,201,974 shares of Class A common stock held by ATH Holding and (ii) 999,297 shares of Class A common stock issuable upon the exercise of currently exercisable warrants held by ATH Holding (the “Warrant Shares”). ATH Holding is a wholly-owned subsidiary of Anthem.

     

      (b)

    Percent of Class

     

    (i) Anthem:    10.1%
    (ii) ATH Holding:    10.1%

    The percentage of shares beneficially owned is based on 29,293,831 and 1,405,259 shares of the Issuer’s Class A common stock and Class B common stock, respectively, outstanding as of November 5, 2021, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 9, 2021, plus the Warrant Shares.

     

      (c)

    Number of shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote

     

    (A) Anthem:    0
    (B) ATH Holding:    0

     

      (ii)

    Shared power to vote or to direct the vote

     

    (A) Anthem:    3,201,271
    (B) ATH Holding:    3,201,271

     

      (iii)

    Sole power to dispose or to direct the disposition of

     

    (A) Anthem:    0
    (B) ATH Holding:    0

     

      (iv)

    Shared power to dispose or to direct the disposition of

     

    (A) Anthem:    3,201,271
    (B) ATH Holding:    3,201,271


    Item 5.

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

    Not Applicable

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

    Not Applicable

     

    Item 8.

    Identification and Classification of Members of the Group

    Not Applicable

     

    Item 9.

    Notice of Dissolution of Group

    Not Applicable

     

    Item 10.

    Certification

    Not Applicable


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth

    in this statement is true, complete and correct.

    Date: February 22, 2022

     

    ANTHEM, INC.
    By:  

    /s/ Katheen S. Kiefer

    Name:   Kathleen S. Kiefer
    Title:   Vice President, Legal and Corporate Secretary

     

    ATH HOLDING COMPANY, LLC
    By:  

    /s/ Katheen S. Kiefer

    Name:   Kathleen S. Kiefer
    Title:   Secretary


    EXHIBIT INDEX

     

    Exhibit Number

      

    Exhibit

    99.1    Joint Filing Agreement dated February 22, 2022 by and between Anthem, Inc. and ATH Holding Company, LLC
    Get the next $SERA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SERA

    DatePrice TargetRatingAnalyst
    12/15/2025$5.00Buy
    Jefferies
    3/30/2022$18.00 → $4.00Buy → Neutral
    Citigroup
    11/19/2021$19.00Outperform
    Oppenheimer
    10/15/2021Outperform
    Cowen
    8/9/2021Outperform
    William Blair
    8/9/2021Outperform
    Cowen
    8/9/2021$18.00Buy
    Citigroup
    More analyst ratings

    $SERA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kamdar Kim P. disposed of 30,920 shares and acquired 3,231 shares, increasing direct ownership by 11% to 32,573 units (SEC Form 4)

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    2/4/26 5:03:47 PM ET
    $SERA
    Medical Specialities
    Health Care

    Chief Information Officer Harrison Robert Gardner sold $5,940 worth of shares (2,000 units at $2.97), decreasing direct ownership by 2% to 82,788 units (SEC Form 4)

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    1/27/26 5:12:53 PM ET
    $SERA
    Medical Specialities
    Health Care

    Chief Information Officer Harrison Robert Gardner sold $6,000 worth of shares (2,000 units at $3.00), decreasing direct ownership by 2% to 84,788 units (SEC Form 4)

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    12/30/25 6:41:19 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    SEC Filings

    View All

    SEC Form 144 filed by Sera Prognostics Inc.

    144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    1/27/26 4:18:25 PM ET
    $SERA
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Sera Prognostics Inc.

    SCHEDULE 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    1/16/26 2:45:31 PM ET
    $SERA
    Medical Specialities
    Health Care

    Sera Prognostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)

    1/8/26 5:20:58 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Sera Prognostics with a new price target

    Jefferies initiated coverage of Sera Prognostics with a rating of Buy and set a new price target of $5.00

    12/15/25 10:01:13 AM ET
    $SERA
    Medical Specialities
    Health Care

    Sera Prognostics downgraded by Citigroup with a new price target

    Citigroup downgraded Sera Prognostics from Buy to Neutral and set a new price target of $4.00 from $18.00 previously

    3/30/22 7:52:32 AM ET
    $SERA
    Medical Specialities
    Health Care

    Oppenheimer initiated coverage on Sera Prognostics with a new price target

    Oppenheimer initiated coverage of Sera Prognostics with a rating of Outperform and set a new price target of $19.00

    11/19/21 4:55:47 AM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Landmark Study Finds PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications

    Published in the journal PREGNANCY, the PRIME Study demonstrates significant improvements in neonatal outcomes with early risk screening and targeted interventions. SALT LAKE CITY, Jan. 7, 2026 /PRNewswire/ -- A randomized controlled trial of 5,018 women has found that a simple blood test, when paired with targeted interventions, can significantly reduce the risk of preterm birth and improve outcomes for newborns. The findings, published in PREGNANCY, the peer-reviewed journal of the Society for Maternal-Fetal Medicine, highlight the effectiveness of the PreTRM Test in identifying women at higher risk for spontaneous preterm birth and guiding preventive care.

    1/7/26 8:30:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    Sera Announces Publication Acceptance for PRIME Study

    The PRIME study, one of the largest studies on preterm birth, has been accepted for publication by a medical journal following abstract presentation earlier this year SALT LAKE CITY, Nov. 24, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the findings of the Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study were accepted for publication in a peer-reviewed  journal.

    11/24/25 8:00:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    $SERA
    Financials

    Live finance-specific insights

    View All

    SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    SALT LAKE CITY, Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2025 ended September 30, 2025. Third Quarter and Recent Highlights: Meaningful progress on payer initiatives, including an inaugural pilot in Nevada actively enrolling Medicaid patients, while engaging with multiple payers across thirteen states, collectively representing a significant

    11/13/25 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2025 FINANCIAL RESULTS ON NOVEMBER 13, 2025

    SALT LAKE CITY, Oct. 30, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report third quarter fiscal year 2025 financial results on Thursday November 13, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

    10/30/25 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

    SALT LAKE CITY, Aug. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2025 ended June 30, 2025. Second Quarter and Recent Highlights: Ongoing progress in engaging Medicaid plans in targeted states with prior PreTRM clinical study experience. Notable traction in two particular states with above-average premature birth rates, presenting strong commercial o

    8/6/25 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

    SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    11/14/24 5:46:12 PM ET
    $SERA
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

    SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    11/4/24 7:19:49 AM ET
    $SERA
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Sera Prognostics Inc.

    SC 13G - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    4/1/24 7:33:43 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer

    SALT LAKE CITY, Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker testing to help deliver information to doctors and patients, today announced the appointment of Tiffany Inglis, MD, FACOG, as Chief Medical Officer. With extensive clinical leadership expertise, Dr. Inglis will lead Sera's clinical operations to establish the company as a leader in women's health diagnostics to improve the health of pregnant women and newborns. Dr. Inglis joins Se

    10/1/25 8:05:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER

    Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.

    5/8/25 4:40:00 PM ET
    $SERA
    Medical Specialities
    Health Care